Basilea News Basilea News en Mon, 29 Aug 2016 16:37:48 +0200 Mon, 29 Aug 2016 16:37:48 +0200 Chameleon CMS (Webmaster Webmaster) (Webmaster Webmaster) <![CDATA[Basilea announces distribution agreement with Hikma for CRESEMBA® (isavuconazole) in the MENA region]]>
  • Basilea extending its agreement with Hikma to include antifungal CRESEMBA® in addition to antibiotic Zevtera®
  • ]]>
    Wed, 17 Aug 2016 07:15:00 +0200
    <![CDATA[Basilea reports 2016 half-year results - CRESEMBA® launched in key European markets]]>
  • Antifungal CRESEMBA® (isavuconazole) launched in first European markets
  • Entered contract with BARDA for the development and potential US registration of the antibiotic ceftobiprole (European trade name Zevtera® or Mabelio®)
  • Half-year cash and financial investments of CHF 311 million
  • ]]>
    Mon, 15 Aug 2016 07:15:00 +0200
    <![CDATA[Basilea's antifungal CRESEMBA® (isavuconazole) launched in Italy]]> Mon, 27 Jun 2016 07:15:00 +0200 <![CDATA[Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting]]>
  • Clinical data reported from completed phase 1/2a study of BAL101553, with once-weekly 2-hour infusion showing signals of clinical activity
  • Design of ongoing phase 1/2a study with once-daily oral BAL101553 presented, with four dose cohorts completed
  • Design of ongoing BAL3833 oral phase 1 study presented, with four dose cohorts completed
  • ]]>
    Thu, 09 Jun 2016 07:15:00 +0200
    <![CDATA[Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders]]> Thu, 21 Apr 2016 18:30:10 +0200 <![CDATA[Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting]]>
  • Tumor checkpoint controller BAL101553 demonstrates pre-clinical activity in treatment-refractory glioblastoma models as single agent and in combination treatment
  • PanRAF/SRC kinase inhibitor BAL3833 inhibits tumor growth in preclinical KRAS-driven cancer models
  • ]]>
    Thu, 21 Apr 2016 07:15:00 +0200
    <![CDATA[Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program]]> Wed, 20 Apr 2016 07:15:00 +0200 <![CDATA[Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)]]>
  • Post-hoc analysis on clinical response of ceftobiprole in staphylococcal bacteremia
  • ]]>
    Fri, 15 Apr 2016 07:15:00 +0200
    <![CDATA[Basilea issues agenda for Annual General Meeting of Shareholders]]>
  • Dr. Martin Nicklasson has determined not to stand for re-election as Chairman but will stand for re-election as Member of the Board
  • Domenico Scala nominated as new Chairman of the Board
  • ]]>
    Tue, 15 Mar 2016 07:15:00 +0100
    <![CDATA[Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis]]> Wed, 09 Mar 2016 07:15:00 +0100